Order Article Reprints

Minetto P, Candoni A, Guolo F, Clavio M, Zannier ME, Miglino M, Dubbini MV, Carminati E, Sicuranza A, Ciofini S, et al. Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden. Cancers. 2021; 13(1):34. https://doi.org/10.3390/cancers13010034

Minetto, Paola, Anna Candoni, Fabio Guolo, Marino Clavio, Maria Elena Zannier, Maurizio Miglino, Maria Vittoria Dubbini, Enrico Carminati, Anna Sicuranza, Sara Ciofini, and et al. 2021. "Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden" Cancers 13, no. 1: 34. https://doi.org/10.3390/cancers13010034

Minetto, P., Candoni, A., Guolo, F., Clavio, M., Zannier, M. E., Miglino, M., Dubbini, M. V., Carminati, E., Sicuranza, A., Ciofini, S., Colombo, N., Pugliese, G., Marcolin, R., Santoni, A., Ballerini, F., Lanino, L., Cea, M., Gobbi, M., Bocchia, M., ... Lemoli, R. M. (2021). Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden. Cancers, 13(1), 34. https://doi.org/10.3390/cancers13010034